Overview

Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
0
Participant gender:
All
Summary
There is heterogeneity in patients with depression. Many scholars propose that individualization of antidepressant achieves better outcomes. However, the scientific theoretical basis of individualized treatment is still quite weak. Different clinical subtypes of depression and their possible biomarkers are critically needed to provide the individualization with theoretical base. Diagnostic types of major depression disorder (MDD) based on the Theory of Traditional Chinese Medicine (TCM) and possible differentiations in neurobiochemistry, metabonomics and neuroimaging could be one of ways to explore the biomarkers and support the theory of the individualized treatment. The hypothesized results will be of help to clarify the biological basis of MDD with LDQS and with DBHS, to provide the TCM with further scientific evidence, to explore the pathogenesis of depression, to improve the objective diagnosis of depression, and to promote targeted interventions by Western medicine, TCM or both.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Zhejiang Provincial Tongde Hospital
Collaborator:
The University of Hong Kong
Treatments:
Clonazepam
Venlafaxine Hydrochloride
Criteria
Inclusion Criteria:

1. Had a diagnosis of major depressive disorder according to DSM-V and TCM criteria of
'pattern of Liver Depression and Qi Stagnation (LDQS)' or'pattern of Deficiency of
Both Heart and Spleen (DBHS)

2. The severity of the symptoms is moderate or severe, confirmed by a 35 or greater of
Hamilton Rating Scale for Depression(HAMD) score

3. Absence of brain and/or severe physical diseases

4. 18-65years old

Exclusion Criteria:

1. In pregnancy，brain and other severe medical conditions

2. Psychoactive substance abuse

3. Had a diagnosis of bipolar disorder